CYTK
Cytokinetics Soars: Q1 2026 Earnings a Testament to Emerging Promise of Muscle-Focused Specialty Biopharma
Cytokinetics, Inc. has reported a remarkable first quarter in 2026, exceeding expectations and marking significant milestones in the company's journey towards becoming a leading muscle-focused specialty biopharma. The highlight of the quarter was undoubtedly the commercial launch of MYQORZO, the company's first approved medicine for the